Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort studySalim Yusuf, Gilles R. Dagenais, Khalid F. AlHabib et al.|The Lancet|2019Cited by 2k
Reducing the Global Burden of Cardiovascular Disease, Part 1Philip Joseph, Salim Yusuf, Darryl P. Leong et al.|Circulation Research|2017Cited by 1.1k
Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditisJohn R. Power, Ellen Warner, Joachim Alexandre et al.|Archives of cardiovascular diseases|2022Cited by 38
Immune checkpoint inhibitor-associated myocarditis: a novel risk scoreJohn R. Power, Anju Nohria, Charles Dolladille et al.|European Heart Journal|2025Cited by 34
Immune Checkpoint Inhibitor–Associated Cardiovascular Toxic EffectsJoerg Herrmann, Joshua D. Mitchell, Ana Barac et al.|JAMA Oncology|2025Cited by 10